JenniferEng-WongMD

Oncology • Washington, DC

Assistant Professor, Medicine, Georgetown University School of Medicine

Join to view full profile

Dr. Eng-Wong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Eng-Wong's full profile

Already have an account?

Office
3800 Reservoir Rd Nw
Lombardi Cancer Center
Washington, DC 20007
Phone+1 202-444-4948

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
University of California Davis HealthResidency, Internal Medicine, 1996 - 1999
Stony Brook University Health Sciences Center School of MedicineClass of 1996

Certifications & Licensure

DC State Medical License 2000 - 2013
MD State Medical License 2010 - 2012

Clinical Trials

Raloxifene in Preventing Breast Cancer in Premenopausal Women Start of enrollment: 1998 Dec 01
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3

Publications & Presentations

PubMed

1 citations
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Meta...
Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, Sherene Loi, Aditya Bardia
Clinical Cancer Research. 2024-02-16
Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer.
Vikram Malhi, Priya Agarwal, Mary R Gates, Lichuan Liu, Jianshuang Wang
Cancer Research Communications. 2023-12-15
7 citations
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
Jackson Liang, Ellen Rei Ingalla, Xiaosai Yao, Bu-Er Wang, Lisa Tai
Science Translational Medicine. 2022-09-21

Authored Content

Long-Term Efficacy Analysis of the Randomised, Phase II TRYPHAENA Cardiac Safety Study: Evaluating Pertuzumab and Trastuzumab plus Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast CancerJanuary 2018